AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study
BioSpace
AbbVie's etentamig has a relatively cleaner safety profile and an administration schedule that could give it an edge over other BCMA-targeting multiple myeloma therapies on the market, according to BM
pharminent
September 4, 2026 (Last updated: September 7, 2026)
BioSpace
AbbVie’s etentamig has a relatively cleaner safety profile and an administration schedule that could give it an edge over other BCMA-targeting multiple myeloma therapies on the market, according to BM